GAN Structure Synthesis
Design pharmaceutical microstructures in silico with digiM’s GAN technology. Simulate formulations, predict performance, and accelerate development.

Digital Formulation Development
Our structure synthesis platform is a patent-pending approach that uses generative adversarial networks (GAN) to create 3D digital image volumes replicated from imaging scans (WO2024138171A1). Through training on microscopic images like X-ray micro-CT and FIB-SEM datasets, the platform learns physical characteristics of a product which are screened in generation of a replicated image data. It can then generate new microscopic datasets with controlled modifications, while adhering to the inherent structure of the original sample (eg a different drug amount, but with the same particle size). This approach allows scientists to digitally design new formulations without manufacturing them, exploring parameters like drug load, dispersion patterns, and particle size.
Image-Informed Digital Twins
Generate realistic 3D microstructures directly from images that capture critical quality attributes for predictive analysis without physical experimentation.
Microstructure Generation
Easily adjust CQA's such as porosity, particle size, or drug loading to simulate a wide range of design scenarios and manufacturing outcomes.
Regulatory-Ready Support
Support regulatory filing, Q3-sameness assessments, and formulation justifications with high-fidelity 3D structural evidence.
Development & Cost Savings
Reduce the need for iterative lab work by replacing physical trials with fast, AI-driven simulations—saving time, material, and development costs.
For pharmaceutical scientists, this means a powerful new tool to speed up formulation design, reduce experimental costs, and support regulatory decisions. The software can be used in combination with in-silico dissolution models to simulate drug release profiles and assess how changes in formulation or processing may impact performance. By digitizing and simulating key quality attributes, structure synthesis helps teams make informed decisions earlier, with fewer physical trials, and greater confidence in final product performance.
Explore Microstructural Impacts on Performance
Explore how subtle shifts in microstructure like API distribution, particle size, or dispersion affect performance without making new batches. Structure Synthesis artificial intelligence can simulate these complex design scenarios in silico, testing ideas that may be too expensive, time-consuming, or impossible to make physically. Whether you are fine-tuning a controlled-release profile, managing risk from manufacturing variability, or comparing formulation strategies, this digital sandbox opens the door to a new kind of formulation intelligence built on exploration, not trial and error.

Ready to See it in Action?
Whether you're designing new formulations, optimizing release, or demonstrating Q3 sameness, structure synthesis bring speed and clarity to your pharmaceutical development processes. If you're ready to revolutionize your research and development, contact us to learn more about how GAN can support your product portfolio.
Revolutionize your Product Development
Learn how to advance your pharmaceutical development with GAN's advanced AI capabilities today.
